February 13, 2017
Allergan buys medical aesthetics specialist Zeltiq for $2.475 billion
Allergan has made another acquisition deal in expanding its medical aesthetics portfolio by buying Zeltiq Aesthetics for $2.475 billion.
Pharmaceuticals, Biotechnology and Life Sciences
Category: North America
February 13, 2017
Anavex appoints Peter Donhauser to its Board
Anavex Life Sciences, a clinical-stage biopharmaceutical company developing differentiated therapeutics for the treatment of neurodegenerative and neurodevelopmental diseases including Alzheimer’s disease, other central nervous system (CNS) diseases, pain and various types of cancer, has appointed Peter Donhauser, D.O. to its Board of Directors.
February 13, 2017
Pharmaceutical grade silica gel market could worth $71.05 million by 2025
The global pharmaceutical grade silica gel market is projected to reach a market size of $71.05 million by 2025.
February 13, 2017
Orion finds replacement for its retiring Senior Vice President for Research and Development in Eli Lilly
Orion Group has announced that Dr. Reijo Salonen, M.D., Ph.D., Senior Vice President for Research and Development of the Orion Group and member of the Executive Management Board of the Orion Group will step aside from his current positions as of 21 February 2017.
February 10, 2017
U.S. scientists get $87 million Grand Challenge awards to quicken battle against cancer
Cancer Research UK (CR UK), the world’s largest not-for-profit cancer research organization, has today announced that six leading U.S. scientists are among the winners of a global competition to help overcome the biggest challenges facing cancer research.
February 10, 2017
Immunomedics, Seattle Genetics in $2B cancer drug deal. ‘Seattle’ buys 2.8% stake
Immunomedics Inc has concluded a $2 billion worth deal with Seattle based developer of antibody-drug conjugates (ACDs) for treating late stage cancer based on which Seattle Genetics will develop, fund, manufacture and commercialize IMMU-132, Immunomedics’ proprietary solid tumor therapy candidate.
February 10, 2017
Neurocrine, BIAL in exclusive USA and Canada licensing Opicapone deal
Neurocrine Biosciences has made a deal with BIAL to develop and sell Ongentys opicapone inhibitor for Parkinson’s patients, in North America.
February 10, 2017
Amgen co-founder, Amarantus director Dr Joseph Rubinfeld, dies
Amgen co-founder Dr. Joseph Rubinfeld, who was an independet director of Amarantus BioScience Holdings has died.
February 10, 2017
Canadian Crescita seeks new CFO
Canadian commercial dermatology company Crescita Therapeutics has named its Corporate Controller Ms. Muneerah Kanji as Interim Chief Financial Officer.
February 10, 2017
Aytu sales up by 47% from September for first ever $1M-plus sales quarter. Reduces net loss
Aytu BioScience, a drugmaker focused on urology products, has increased gross product sales by 47% from the quarter ended September 30, 2016 to the quarter ended December 31, 2016, from $925,000 to $1,358,000, getting its first ever $1M-plus quarter sales.